Ergoactive ergothioneine for maternal and infant health applications

Overview

Blue California is advancing research on ergothioneine (ET), a naturally occurring dietary nutrient recognized as a longevity vitamin, to establish its critical role in maternal and infant health. Preliminary evidence suggests ET is transferred from mother to child via the placenta and breast milk through a specific transporter protein, positioning it as a pivotal nutrient for safeguarding reproductive health, pregnancy outcomes, and early development.

The proposed research aims to strengthen the scientific foundation for ET supplementation in pregnant and lactating women by defining healthy plasma ET levels, investigating links between ET status and conditions such as pre-eclampsia, and determining whether supplementing lactating mothers enhances ET delivery to infants. These efforts will lay the groundwork for future intervention studies and support evidence-based product development in the maternal and infant nutrition space.

Technical specifications

Key research objectives:

• Assess plasma ET levels in matched maternal and cord blood as well as breast milk to establish baseline healthy ranges
• Investigate associations between cord and child plasma ET levels and cognitive, behavioral, and developmental outcomes
• Study the link between maternal plasma ET levels and pre-eclampsia incidence in Asian populations, extending previous Caucasian cohort findings
• Determine whether ET supplementation in lactating mothers augments ET delivery to children through breastfeeding

Supporting evidence and mechanism:

• Animal studies demonstrate ET reduces embryo malformations in diabetic pregnant rats by inhibiting glucose-mediated oxidative damage
• In vitro bovine embryo studies show ET improves embryo quality indicators and cryotolerance
• Rat models of pre-eclampsia show ERG supplementation reduces hypertension and improves pup weight
• ET is a robust antioxidant and cellular protector with a dedicated transporter expressed in the placenta and mammary glands
• Animal data indicate ET promotes hippocampal differentiation, neurogenesis, and synapse formation, supporting early brain development

Regulatory status:

• Approved by the European Food Safety Authority for use in pregnant women and infants
• GRAS (Generally Recognized as Safe) status with no objection from the US FDA

Technology readiness level

ErgoActive ergothioneine is commercially available as a branded specialty ingredient produced through proprietary precision fermentation and bioconversion processes. The ingredient has established regulatory approvals for use in maternal and infant applications in key markets. The proposed validation studies represent a critical next step to expand the clinical evidence base, particularly in understudied populations, and to define optimal plasma ET levels and supplementation protocols. Successful completion of these objectives will enable partners to develop scientifically supported products targeting pregnancy wellness, pre-eclampsia prevention, and infant cognitive and developmental health.